503b pharmacy semaglutide The FDA has proposed to bar outsourcing facilities from bulk compounding and tirzepatide. The shortage-list pathway already closed in 2024 and 2025; this proposal would remove the remaining bulks-list route FDA Intensifies Crackdown on GLP-1

Create a Provider Account Collapsible content Research Partners As a research partner, your goal is to ensure accuracy and reproducibility

This approach isn't suitable for everyone, particularly those with diabetes on insulin or sulfonylureas, pregnant or breastfeeding women, people with a history of eating disorders, those with kidney disease, or frail individuals

First raid on UK illegal weight loss drug factory Published The first illicit production facility for weight loss medicine found in the UK has been dismantled

However, they may come with side effects such as nausea, diarrhea, vomiting, abdominal pain, and constipation